T. Rowe Price Associates’s XBiotech XBIT Stock Holding History

T. Rowe Price Associates’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-23,625	Closed	-$183K	–	3064
2024 Q3	$183K	Hold	23,625	–	–	﹤0.01%	2684
2024 Q2	$122K	Buy	23,625 +6,025	+34%	+$46.5K	﹤0.01%	2719
2024 Q1	$144K	Hold	17,600	–	–	﹤0.01%	2704
2023 Q4	$71K	Hold	17,600	–	–	﹤0.01%	2764
2023 Q3	$73K	Hold	17,600	–	–	﹤0.01%	2719
2023 Q2	$105K	Hold	17,600	–	–	﹤0.01%	2695
2023 Q1	$61K	Hold	17,600	–	–	﹤0.01%	2763
2022 Q4	$62K	Hold	17,600	–	–	﹤0.01%	2786
2022 Q3	$64K	Hold	17,600	–	–	﹤0.01%	2800
2022 Q2	$99K	Buy	17,600 +3,146	+22%	+$21.2K	﹤0.01%	2756
2022 Q1	$125K	Buy	+14,454	New	+$145K	﹤0.01%	2811
2021 Q4	–	Sell	-12,154	Closed	-$157K	–	3044
2021 Q3	$157K	Hold	12,154	–	–	﹤0.01%	2771
2021 Q2	$201K	Buy	12,154 +340	+3%	+$5.77K	﹤0.01%	2731
2021 Q1	$203K	Buy	+11,814	New	+$221K	﹤0.01%	2690
2017 Q4	–	Sell	-11,648	Closed	-$51K	–	2617
2017 Q3	$51K	Hold	11,648	–	–	﹤0.01%	2544
2017 Q2	$55K	Hold	11,648	–	–	﹤0.01%	2521
2017 Q1	$192K	Hold	11,648	–	–	﹤0.01%	2401
2016 Q4	$118K	Hold	11,648	–	–	﹤0.01%	2457
2016 Q3	$157K	Buy	+11,648	New	+$171K	﹤0.01%	2384

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates's XBIT Position: Q4 2024 in Review

T. Rowe Price Associates sold out of XBiotech (XBIT) in Q4 2024, closing a stake of 23,625 shares — an estimated $183K sold.

T. Rowe Price Associates first reported a position in XBIT in Q3 2016 and held it in 19 quarters. The position peaked at $203K in Q1 2021. 53 funds tracked by Wall St. Rank hold XBIT as of Q4 2024.

T. Rowe Price Associates reported no remaining XBiotech position as of Q4 2024 after selling out during the quarter.
T. Rowe Price Associates sold 23,625 XBiotech shares in Q4 2024, an estimated $183K.
T. Rowe Price Associates first reported a position in XBiotech in Q3 2016 and held it in 19 quarters.
T. Rowe Price Associates's XBiotech position peaked at $203K in Q1 2021.
53 funds tracked by Wall St. Rank held XBiotech as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.